Rivaroxaban-Associated Hepatotoxicity: a Clinical Case and Literature Review
Abstract
Direct oral anticoagulants (not vitamin K antagonists), unlike standard oral anticoagulants (e.g. warfarin), have a predictable manifestation of the anticoagulant effect and the possibility of using a fixed dose without the need for constant monitoring of the anticoagulant effect. The rapid onset and cessation of the effect of direct oral anticoagulants, the relatively low likelihood of interaction with food and other drugs compared to warfarin, have expanded the possibilities of anticoagulant therapy.
Direct oral anticoagulants, particularly rivaroxaban, are widely used for deep vein thrombosis/pulmonary embolism prevention and treatment, and for stroke prevention in patients with atrial fibrillation. Awareness of side effects is mostly associated with bleeding risks while other problems with the use of this medication attract less physicians’ attention. These side effects mainly include liver damage and some other rare side effects. This article describes a clinical case of rivaroxaban-associated drug-induced liver injury in patient with first diagnosed atrial fibrillation and normal baseline liver enzymes. A literature review focused on this problem is also presented.
About the Authors
B. A. Tatarsky
Almazov National Research Medical Center
Russian Federation
Russian Federation
MD, PhD, Professor, Chief Researcher, Clinical Arrhythmology Research Laboratory,
Akkuratova ul. 2, St. Petersburg, 197341
N. V. Kazennova
Almazov National Research Medical Center
Russian Federation
Russian Federation
MD, PhD, Researcher, Clinical Arrhythmology Research Laboratory,
Akkuratova ul. 2, St. Petersburg, 197341
D. A. Napalkov
I.M. Sechenov First Moscow State Medical University (Sechenov University)
Russian Federation
Russian Federation
MD, PhD, Professor, Chair of Faculty Therapy №1,
Trubetskaya ul. 8-2, Moscow, 119991
References
1. Harder S., Graff J. Novel oral anticoagulants: clinical pharmacology, indications and practical considerations. Eur J Clin Pharmacol. 2013;69:1617-33. DOI:10.1007/s00228-013-1510-z.
2. Tajiri K., Shimizu Y. Practical guidelines for diagnosis and early management of druginduced liver injury. World J Gastroenterol. 2008;14(44):6774-85. DOI:10.3748/wjg.14.6774.
3. Navarro V.J., Senior J.R. Drug-related hepatotoxicity. N Engl J Med. 2006;354(7):731-9. DOI:10.1056/NEJMra052270.
4. Lauschke V., Ingelman-Sundberg M. The importance of patient-specific factors for hepatic drug response and toxicity. Int J Mol Sci. 2016;17:1714. DOI:10.3390/ijms17101714.
5. Goldberg D.S., Forde K.A., Carbonari D.M., et al. Population-representative incidence of drug-induced acute liver failure based on an analysis of an integrated health care system. Gastroenterology. 2015;148:1353-61. DOI:10.1053/j.gastro.2015.02.050.
6. Benichou C. Criteria of drug-induced liver disorders. Report of an international consensus meeting. J Hepatol. 1990;11(2):272-6. DOI:10.1016/0168-8278(90)90124-A.
7. Aithal G.P., Watkins P.B., Andrade R.J., et al. Case definition and phenotype standardization in druginduced liver injury. Clin Pharmacol Ther. 2011;89(6):806-15. DOI:10.1038/clpt.2011.
8. Liakoni E., Ratz Bravo A.E., Krahenbuhl S. Hepatotoxicity of new oral anticoagulants (NOACs). Drug Saf. 2015;38:711-20. DOI:10.1007/s40264-015-0317-5.
9. Agnelli G., Eriksson B.I., Cohen A.T., et al. Safety assessment of new antithrombotic agents: lessons from the EXTEND study on ximelagatran. Thromb Res. 2009;123:488-97. DOI:10.1016/j.thromres.2008.02.017.
10. Turpie A.G., Lassen M.R., Davidson B.L., et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial. Lancet. 2009;373:1673-80. DOI:10.1016/S0140-6736(09)60734-0.
11. Watkins P.B., Desai M., Berkowitz S.D., et al. Evaluation of drug-induced serious hepatotoxicity (eDISH): application of this data organization approach to phase III clinical trials of rivaroxaban after total hip or knee replacement surgery. Drug Saf. 2011;34:243-52. DOI:10.2165/11586600-000000000-00000.
12. Caldeira D., Barra M., Santos A.T., et al. Risk of drug-induced liver injury with the new oral anticoagulants: systematic review and meta-analysis. Heart. 2014;100:550-6. DOI:10.1136/heartjnl-2013-305288.
13. Alonso A., MacLehose R.F., Chen L.Y., et al. Prospective study of oral anticoagulants and risk of liver injury in patients with atrial fibrillation. Heart. 2017;103:834-9. DOI:10.1136/heartjnl-2016-310586.
14. Raschi E., Poluzzi E., Koci A., et al. Liver injury with novel oral anticoagulants: assessing post-marketing reports in the US Food and Drug Administration adverse event reporting system. Br J Clin Pharmacol. 2015;80:285-93. DOI:10.1111/bcp.12611.
15. Licata A., Puccia F., Lombardo V., et al. Rivaroxaban-induced hepatotoxicity: review of the literature and report of new cases. Eur J Gastroenterol Hepatol. 2018;30(2):226-32. DOI:10.1097/MEG.0000000000001030.
16. Cordeanu M., Gaertner S., Bensalah N., et al. Rivaroxaban induced liver injury: a cholestatic pattern. Int J Cardiol. 2016;216:97-8. DOI:10.1016/j.ijcard.2016.04.063.
17. Lambert A., Cordeanu M., Gaertner S., et al. Rivaroxaban-induced liver injury: results from a venous thromboembolism registry. Int J Cardiol. 2015;191:265-6. DOI:10.1016/j.ijcard.2015.04.248.
18. Glenn K., Chen P., Musleh M., et al. A rare case of rivaroxaban causing delayed symptomatic hepatocellular injury and hyperbilirubinemia. Case Rep Gastrointest Med 2017; 2017: 5678187. DOI:10.1155/2017/5678187.
19. Baig M., Wool K.J., Halanych J.H., et al. Acute liver failure after initiation of rivaroxaban: a case report and review of the literature. N Am J Med Sci. 2015;7:407-10. DOI:10.4103/1947-2714.166221.
20. Tujios S., Fontana R.J. Mechanisms of drug-induced liver injury: from bedside to bench. Nat Rev Gastroenterol Hepatol. 2011;8:202-11. DOI:10.1038/nrgastro.2011.22.
21. Leise M.D., Poterucha J.J., Talwalkar J.A. Drug-induced liver injury. Mayo Clin Proc. 2014;89:95- 106. DOI:10.1016/j.mayocp.2013.09.016.
22. Godoy P., Hewitt N.J., Albrecht U., et al. Recent advances in 2D and 3D in vitro systems using primary hepatocytes, alternative hepatocyte sources and non-parenchymal liver cells and their use in investigating mechanisms of hepatotoxicity, cell signaling and ADME. Arch Toxicol. 2013;87:1315-530. DOI:10.1007/s00204-013-1078-5.
23. Gong I.Y., Kim R.B. Importance of pharmacokinetic profile and variability as determinants of dose and response to dabigatran, rivaroxaban, and apixaban. Can J Cardiol. 2013;29:S24-33. DOI:10.1016/j.cjca.2013.04.002.
Review
For citations:
Tatarsky B.A., Kazennova N.V., Napalkov D.A. Rivaroxaban-Associated Hepatotoxicity: a Clinical Case and Literature Review. Rational Pharmacotherapy in Cardiology. 2019;15(5):675-680. (In Russ.)
Views:
582
Email this article 